Drug row
Prescription drug Prempro, used to treat menopausal symptoms, is under the scanner in the US following a government study that has linked it to other health problems. Class action suits have been brought against the drug's maker, Wyeth Pharmaceuticals. Company spokesperson Natalie de Vane, however, claims the charges are baseless.
The plaintiffs are seeking to inform the public that consumers of Prempro, a combination of oestrogen and progestin, are at an increased risk of invasive breast cancer, coronary heart disease, stroke and pulmonary embolism. They have also contended that compensation be given to victims for personal injuries and a fund instituted for all users of the drug for medical monitoring. "Even if the plaintiffs have a valid claim, it will be difficult to prove,' feels Boston lawyer Michael Hugo.
Related Content
- Order of the National Green Tribunal regarding discharge of wastewater by a drug industry, Nalagarh, Himachal Pradesh, 25/09/2023
- Global progress report on sustainable development goal 16 indicators: a wake-up call for action on peace, justice and inclusion
- Order of the Supreme Court regarding price control of life saving drugs, 13/09/2023
- Why Nimesulide hasn't been banned: Delhi HC to government of India, 01/09/2023
- Engaging the private sector for health SDGs: lessons from India’s National Tuberculosis Elimination Programme
- National policy on research & development and innovation in the pharma-med tech sector in India